In the area of Health Innovation, several research groups at PSI are engaged in the study of fundamental questions regarding biology and cancer therapy. For example, they explore the structure of proteins – extremely complex biomolecules that are responsible for many different functions in organisms. Using PSI’s large research facilities, scientists also explore processes in biological tissue in order to fully understand their function and the development of specific diseases or deterioration processes. The ultimate goal is to find medicines that allow people to live as healthy a life as possible.
Patients with specific types of cancer are treated at the proton therapy facility on the PSI campus. Radiopharmaceuticals provide cancer treatments for very small tumours distributed throughout the body.
Find out more at: Overview Health Innovation
The European Research Council approves PSI projects for the development of a quantum computer and brain research worth about 5 million euros.
PSI scientists have shed light on the structure of an important component of the eye: CNG ion channels whose job is to relay optical signals to the brain.
This gallery presents five people who have been treated at the PSI's Center for Proton Therapy.
Kantonsspital Baden and the Paul Scherrer Institute PSI have signed a cooperation agreement.
In partnership with Roche, PSI scientists are developing new, potentially more efficient catalysts for manufacturing active substances for drug therapies.
25 November 1996: a world first for PSI’s Center for Proton Therapy in treating a cancer patient using the spot-scanning technique.
On 9 November 2021 a lung cancer patient was given proton therapy at the Paul Scherrer Institute PSI for the first time in Switzerland.
PSI researchers identify potential active agent against several unicellular parasites – including the pathogens that cause malaria and toxoplasmosis.
PSI researchers have developed a new method to attach proteins to the surface of virus-like particles.
The University Hospital of Zurich uses proteins made at PSI for Europe’s first large-scale serology study on coronavirus prevalence in Switzerland.
Crystal structure analysis, computer models, cell cultures – to pursue research on Sars-CoV-2, PSI is exploring many avenues. An overview.
A research consortium has deciphered the mechanism of CCR5 receptor activation, providing insights for the development of CCR5 drug antagonists for AIDS, cancer, and inflammatory diseases.
Researchers at Goethe University Frankfurt, in cooperation with the PSI have probably discovered another, previously unknown mechanism of action of the antiviral remdesivir.
Using a combination of computer simulations and laboratory experiments, PSI researchers have identified new binding sites for active agents on the vital protein tubulin.
In our bodies, G protein-coupled receptors mediate countless processes. PSI researcher Ramon Guixà talks about how he brings those receptor molecules to life on the computer screen.
Imaging and sequencing techniques combined with machine learning offer researchers countless opportunities to look inside cells with greater precision than ever before. G.V. Shivashankar, lab head at PSI, describes how such information can be used to find answers to pressing questions.
The composition of particulate matter can influence its harmfulness to human health just as much as the amount, PSI researchers show in a newly published study. Experiments and computational modelling showed that in Europe high concentrations of particulate matter harmful to human health occur mainly in metropolitan areas.
At PSI, researchers decipher the structure of the proteins in bacteria and viruses. This knowledge can aid, for example, in the development of drugs against infectious diseases. But before the investigation can begin, an extremely tricky problem has to be solved: the crystallisation of the molecules.